

Study Protocol: Project to Improve Communication About Serious Illness--Hospital Study (PICSII-H)

Principal Investigator: J. Randall Curtis, MD, MPH

Co-Principal Investigator: Ruth A. Engelberg, PhD

Cambia Palliative Care Center of Excellence

University of Washington, Seattle WA

Table of Contents

1) Brief Overview	2
2) Specific Aims:.....	2
3) Research Plan	3
4) Research Design and Methods	4
5) Outcomes	7
6) Analyses.....	9
7) Sample size	10
8) Data management and quality control to achieve scientific rigor.....	10
9) Protocol modifications	11
10) Potential limitations and alternative approaches	11
11) Anticipated findings.....	13

1) Brief Overview

For hospitalized patients with chronic illness, a key component of high-quality care includes goals-of-care discussions (GOCD) conducted early during a hospital stay to identify how patients' goals of care should inform current care plans. These goals-of-care discussions are associated with improved patient and family outcomes and reduced intensity of care at the end of life. Despite their importance, GOCD during a hospitalization often do not occur. The failure to conduct these conversations and to ensure that care received is aligned with patients' wishes for care is particularly a concern for older adults with chronic illness, and particularly those with Alzheimer's disease and related dementias (ADRD).

This study, funded by NIA, evaluates the Jumpstart intervention, the key to which is the "Jumpstart Guide." There are two versions of the Jumpstart Guide being tested, one that is "clinician-facing" and includes information identifying the dates of prior advance care planning documents (e.g., living wills, healthcare directives, durable power of attorney for healthcare) and Physician Orders for Life Sustaining Treatments (POLST forms) in the electronic health record (EHR) to the clinician. It also includes "just-in-time" suggestions for having a GOCD. The other guide is "patient-specific" and "bi-directional". It is patient-specific because it provides goals of care information from patient's self-reported surveys and is then shared with his/her clinician. It is bi-directional because there is one Jumpstart that goes to the clinician and another version that goes to the patient or, if the patient doesn't have decisional capacity, a family member. These one-page Jumpstart Guides include not only indications of prior advance care planning documents (both guides) and preferences (patient-specific guide only) but also tips to improve this communication that are tailored either for clinicians or patients and family members.

The study comprises two linked, complementary randomized trials. Trial 1, a large pragmatic trial, compares usual care with the clinician-facing Jumpstart for hospitalized older adults with serious illness (target n=2000; ADRD subset, target n=400). Trial 2, a comparative effectiveness trial is a three-arm trial that compares the clinician-facing Jumpstart, the bi-directional, patient-specific Jumpstart and usual care (n=600). Subjects are enrolled from the UW Medicine hospitals (Harborview Medical Center, UW Medical Center - Montlake, UW Medical Center – Northwest). For Trial 1, eligible patients are ≥ 55 years, admitted for a minimum of 12 and a maximum of 96 hours prior to study enrollment to inpatient services, without a documented GOCD during admission, and meet criteria for serious illness; hospitalized patients >80 years are also eligible. For Trial 2, eligible patients meet the same criteria and, in addition, must be sufficiently fluent in English to complete questionnaires and not be under COVID precautions to allow in-person recruitment. For Trial 2, eligible family may include any of the following: legal guardians, durable power of attorney for healthcare, spouses, adult children, parents, siblings, domestic partners, other relatives, and friends. In addition, we will conduct qualitative interviews with key stakeholders including patients/families (n=40, subgroup of patients enrolled for Trial 2) and clinicians (n=50 across Trial 1 and Trial 2).

2) Specific Aims:

Specific Aim 1 (Trial 1): Evaluate the effectiveness of a novel clinician-facing Jumpstart, compared with usual care, for improving the quality of care; the primary outcome is EHR documentation of a goals-of-care discussion during the 30 days after enrollment. Secondary outcomes focus on intensity of care: ICU use, ICU and hospital free days, costs of care during the hospitalization, and 7- and 30-day hospital readmission.

Specific Aim 2 (Trial 2): Evaluate the efficacy of the bi-directional, patient-specific Jumpstart compared to the clinician-facing Jumpstart and usual care for improving quality of care; the primary outcome is EHR documentation of a goals-of-care discussion 30 days after enrollment. Secondary outcomes include: intensity of care outcomes from Aim 1 and patient- and family-reported outcomes assessed by surveys at 3-5 days and

4-6 weeks after randomization, including occurrence and quality of goals-of-care discussions in the hospital, goal-concordant care, psychological symptoms, quality of life, and palliative care needs.

Specific Aim 3: Conduct a mixed-methods evaluation of the implementation of both interventions, guided by the RE-AIM framework for implementation science, incorporating quantitative evaluation of intervention reach and adoption, as well as qualitative analyses of interviews with participants, to explore barriers and facilitators to future implementation and dissemination.

3) Research Plan

a) Background and Significance

People near the end of life often receive care they would not choose.^{48,49} The National Academy of Medicine has documented these discrepancies in care and identified advance care planning and goals-of-care discussions as primary mechanisms for addressing them.⁴⁸ This type of communication is a focus for improvement for two key reasons: 1) when goals-of-care discussions occur, they are associated with improved quality of care and patient- and family-centered outcomes including increased quality of life, reduced symptoms of psychological distress, and fewer intensive treatments at the end of life;^{1,7,50,51} and 2) clinicians frequently do not have goals-of-care discussions with their patients until very late in the illness.^{1,3-6}

The value of advance care planning discussions with healthy individuals is a topic of debate; however improving goals-of-care discussions for those with serious illness facing difficult treatment decisions is widely agreed upon as an urgent need that can improve patient outcomes.¹⁻⁶ There is an emerging consensus on this important distinction between ACP for healthy individuals and goals-of-care discussions for those with chronic life-limiting illness and on the critical importance of timely goals-of-care discussions.^{1,7,8} Furthermore, even if advance care planning does occur in the outpatient setting, effective goals-of-care discussions (a component of advance care planning for more proximal decision-making) are still needed for hospitalized patients whose prior preferences may have changed or may not have been specific to the current circumstances.^{52,55,56} In short, for hospitalized patients with chronic illness, a key component of high quality care includes goals-of-care discussions conducted early during a hospital stay that build on prior advance care planning and identify how patients' goals inform current care.^{4,53,57} These early hospital discussions are supported by the National Quality Forum.⁵⁸ Despite their key importance to a large number of patients, early hospital goals-of-care discussions often do not occur.^{4,59} A recent research agenda for serious illness communication, supported by the National Institute on Aging and published in *JAMA Internal Medicine*, highlights the importance of promoting high-quality goals-of-care discussions, as well as the potential opportunity to use the EHR to both identify those patients who would benefit from goals-of-care discussions and to guide clinicians in high-quality discussions.⁸ We propose two complementary trials to examine the effectiveness of such interventions, and we use an innovative hybrid effectiveness-implementation approach that evaluates the interventions and their implementation.²³

b) Innovation

Use of the EHR to identify seriously ill, hospitalized patients without a goals-of-care discussion: Recent research agendas highlight the lack of research utilizing the EHR to implement interventions that improve serious illness communication.^{8,9} We will use a validated EHR-based quality metrics program to identify hospitalized patients over age 55 with chronic serious illness who do not have EHR documentation of a goals-of-care discussion. We have developed an innovative NLP/ML protocol to identify inpatient and outpatient documentation of goals-of-care discussions in any type of EHR note, including admission notes, progress notes, and discharge summaries (*see preliminary data*). In this way, we not only target a population likely to benefit from the intervention but also do so with methods that are generalizable and scalable.¹⁰⁵

Examine both a clinician-facing Jumpstart and a patient-specific Jumpstart in an innovative study design: The intervention is based on our recently completed trial in the outpatient setting of the patient-specific intervention (Jumpstart), which is an individualized communication-priming intervention, targeting both patients and clinicians and providing each with information obtained from patient surveys in order to guide a goals-of-care discussion.² This intervention is innovative because it is one of the few that involves clinicians as well as patients and family members (bi-directional). However, a question raised by reviewers of our prior trial² was whether the individualized survey-based component was necessary, especially given the resources needed to implement it. Therefore, we have developed this innovative study design that combines a large pragmatic trial of a clinician-facing Jumpstart compared to usual care (using a waiver of informed consent to facilitate enrollment and the pragmatic approach) and a smaller comparative effectiveness trial of a bi-directional, patient-specific Jumpstart that will include individual patient or surrogate consent for participation as well as completion of surveys to generate the patient-specific Jumpstart.


Develop an innovative effectiveness-implementation approach that advances implementation and dissemination: Few evidence-based communication interventions are widely adopted. Barriers to implementation include factors at the level of individual patients, clinicians, operating clinical units, and healthcare systems.^{106,107} The RE-AIM (Reach, Effectiveness, Adoption, Implementation, Maintenance) framework systematically addresses these factors and, in turn, translates interventions like Jumpstart into the “real world”.²⁴⁻²⁸ This study will include a novel hybrid effectiveness-implementation approach that can accelerate implementation and dissemination of the interventions after the study by allowing us to evaluate—during the study—strategies and outcomes that will facilitate uptake of the interventions in the future.^{23,28,108-110} This innovative design offers the opportunity to advance implementation science in palliative care and increases the utility of this study.

4) Research Design and Methods

a) Overview

We will conduct two linked, complementary randomized trials of a clinician-facing or a bi-directional, patient-specific intervention to promote and guide goals-of-care discussions for older, seriously ill, hospitalized patients using an innovative method for identifying eligible participants through the EHR. Trial 1 assesses effectiveness of the clinician-facing Jumpstart compared with usual care in a large pragmatic trial not requiring patient or family consent (Aim 1, Trial 1). Trial 2 examines the efficacy of the patient-specific Jumpstart Guide as compared with the clinician-facing Jumpstart and usual care (Aim 2, Trial 2). In addition, we will examine the implementation of the interventions using the RE-AIM framework²⁴⁻²⁷ (Aim 3). Figure 1 provides an overview of the design.

Figure 1:



b) Setting

We will conduct this study with a diverse population drawn from 3 hospitals at UW Medicine, including a university hospital (UW Medical Center, UWMC), a county, safety-net hospital (Harborview Medical Center, HMC), and a community hospital (Northwest Hospital and Medical Center, NWHMC). UWMC provides specialist care for the Pacific Northwest region and has 529 acute care beds and 75 ICU beds. HMC is operated by the University of Washington and has 413 acute care beds and 94 ICU beds. HMC is the only Level 1 Trauma Center serving five states, and its mission population includes inner city poor, recent immigrants, and persons with HIV/AIDS. NWHMC is a community hospital with 218 acute care beds and 15 ICU beds, serving north Seattle with a large geriatric and nursing home resident population. Our prior studies have included each of these sites.^{29,30,79} These 3 sites offer the advantage of caring for diverse patients while also using a unified EHR incorporating EPIC systems into a platform we have been able to access and use.¹⁶⁻²¹

c) Patient population

Eligible patients over 55 will be identified by ICD-10 codes for one or more of the nine chronic conditions used by the Dartmouth Atlas:¹³⁴ dementia, malignant cancer/leukemia, chronic pulmonary disease, coronary artery disease, heart failure, chronic liver disease, chronic renal disease, diabetes with end-organ damage, and peripheral vascular disease. These nine conditions account for 90% of deaths among Medicare beneficiaries in the US.^{135,136} To increase inclusivity of important and under-studied populations, we will also include all hospitalized patients over age 80. Among patients meeting these criteria, we will include only those with no identified documentation of goals-of-care discussions during the current hospitalization and prior to enrollment. For Trial 2, eligible patients or their surrogates will have sufficient English language proficiency to complete surveys.

d) Description of participants

We will collect the following information about study participants.

Patients: Age, race, ethnicity, sex, comorbidities and acute severity of illness including the National Early Warning Score (NEWS). For Trial 2, we will additionally collect education, marital status, health status (SF-1) and income.

Families: Age, race, ethnicity, sex, education, marital status, health status (SF-1), relationship to patient, living situation related to patient.

Clinicians: Age, race, ethnicity, sex, education.

e) Sampling patients with ADRD

Given the dramatically increasing prevalence of ADRD in the US and the rising intensity of care among these patients,^{11,13} it is particularly important that we understand the effect of interventions to improve quality of palliative care in this group. We designed both trials to be powered to examine heterogeneity of treatment effects (HTE) in this important group. For Trial 1, we will plan to continue recruitment to enhance power in this subgroup. For Trial 2, we will prioritize recruitment of patients with ADRD to maximize this subgroup sample size. We hypothesize that the interventions will be equally effective in this population, but that the proportion of patients with decisional capacity will be lower (enrolling more family members). However, we believe it is important to explicitly examine this hypothesis given the unique features of intensity of care at the end of life for this important and increasing population.

f) Randomization

Patients are randomized in a 1:1 ratio in Trial 1 and 1:1:1 ratio in Trial 2 using variable size blocks and stratified for hospital and ADRD vs. no ADRD. Participating family members or legal surrogate decision makers are assigned to the same arm as the corresponding patient.

g) Intervention

Clinician-facing Jumpstart: First, we use automated methods to examine inpatient and outpatient EHR notes prior to the current admission, identifying current code status as well as all prior POLST forms and advance directives; this information is included on Jumpstart Guides to inform discussions. Second, we deliver the Jumpstart Guide to the primary hospital team (all attending and resident physicians and advanced practice providers) via secure email and either a page (Trial 1) or Epic SecureChat message (Trial 2) alerting the physicians to the presence of the Jumpstart Guide in their email, with the addition of in-person delivery of a paper version in Trial 2 only.

Bi-directional Jumpstart (Trial 2 only): First, information about the patient is abstracted from the EHR in the same way as for the Clinician-facing Jumpstart. Second, patients or their legal surrogate decision-maker complete baseline survey items assessing three domains: a) preferences for discussions about goals of care; b) barriers and facilitators for having such discussions; and c) current goals of care. Third, using the EHR and baseline survey, we use the automated algorithm from our prior trial⁹ adapted to the hospital setting using human-centered design methods¹⁰ to create a survey-informed Jumpstart Guide to prompt and guide goals-of-care discussions between the patient and hospital team or, if the patient isn't able, the family member and the hospital team (see supplement for sample Jumpstart Guide). Finally, in the fourth step, we deliver the Jumpstart Guides to the primary team via secure email similar to Trial 1, as well as in-person delivery to members of the team. We also provide a survey-informed Jumpstart Guide to the patient or family, adapted with phrasing and terminology specifically for the patient and family. All Jumpstart Guides are delivered on

the day of randomization with the goal of prompting a goals-of-care discussion early during hospitalization, as supported by the National Quality Forum.¹¹ The bi-directional Jumpstart includes both EHR- and patient-tailored suggestions for conducting goals-of-care discussions based on survey responses. The suggestions are guided by the educational experience of VitalTalk, a nationally-acclaimed program for teaching serious illness communication, and adapted to the inpatient setting,^{12,13} as well as by a human-centered design exercise with hospital clinicians.¹⁰

5) Outcomes

a) Outcomes from the EHR and Death Certificates (Trials 1 and 2):

The primary outcome for both trials is EHR documentation of goals-of-care discussions within 30 days after randomization. Our rationale for this as the primary outcome is that this is the primary target for all interventions and important to diverse stakeholders including patients and their families.^{1,14-17} We will use NLP/ML methods to identify goals-of-care discussions.¹⁸ We will manually review the EHR for goals-of-care discussions using our standard EHR abstraction methods¹⁹⁻²¹ for a randomly selected subset of patients in each trial to evaluate potential misclassification with NLP/ML methods.

Additional outcomes for both trials, obtained from the EHR, include utilization metrics associated with intensity of care (i.e., any ICU admissions, any ED visits, any palliative care consultations, and ICU- and hospital-free days); these outcomes will be assessed at 30 and 90 days after randomization. ICU- and hospital-free days are defined as the number of days alive and outside of the ICU (or hospital) within the specified time period after randomization (i.e. 30 days or 90 days).^{22,23} We will also examine the following outcomes: 1) time to first goals-of-care discussion during the 30 days after randomization; 2) occurrence of any hospital readmissions within 7 and 30 days after discharge from the index hospitalization; and 3) mortality status at 90 days and 1 year after randomization. Costs of care during hospital admission and 30- and 90-days following randomization will be obtained from institutional billing systems. Washington State death certificate data will be used to examine mortality after hospital discharge (Table 1).

b) Outcomes derived from patient- and family-reports (Trial 2 only):

Additional outcomes for Trial 2 will be obtained from patient or family surveys. Surveys will be completed targeting three time points: 1) baseline; 2) 3-5 days after randomization; and 3) 4-8 weeks after randomization. Surveys may be completed in person, online, by mail, or by phone, based on respondents' preferences.

Occurrence and quality of discussions: We use previously validated items to assess the occurrence and quality of goals-of-care communication during the hospitalization after randomization.^{9,24-30} Communication occurrence is assessed with a single item.^{9,25} Quality of goals-of-care communication is assessed with the end-of-life communication scale (QOC_eol) of the Quality of Communication (QOC) survey, developed from qualitative interviews and focus groups with a diverse group of patients, families, and clinicians.^{24,26,28}

Goal-concordant care: Concordance between the care patients want and the care they are receiving will be measured with two questions from SUPPORT.³¹ The first question defines patients' priorities for extending life or ensuring comfort. The second question assesses patients' perceptions of their current treatment using the same two options.³¹ Concordance is defined as a match between preference for care and the type of care currently received, as reported by patients or families. Although most patients want both quality and life-extending care, requiring respondents to pick one is a useful way to identify patients' top priority.³²⁻³⁴ If patients are unable to respond, goals of care are elicited from family as they would be in clinical practice.³⁵

Symptoms of anxiety and depression: Patient and family symptoms of anxiety and depression are assessed with the Hospital Anxiety and Depression Scale (HADS).^{36,37} Patients and families will complete these surveys for themselves only; we do not ask for surrogate report of patients' psychological symptoms. The goal is not to diagnose the clinical syndromes of anxiety or depression, but rather to identify the burden of symptoms.

Utilization: In addition to measuring hospital readmissions through the EHR, we will use patient or family reports of patient emergency department visits, hospitalizations, and outpatient visits following hospital discharge. By using both sources of data, we expect to capture utilization that occurs outside of UW Medicine.

c) Implementation outcomes (Trials 1 and 2)

Assessment of the implementation of the interventions in Aim 3 is guided by the RE-AIM Framework for implementation research³⁸⁻⁴¹ and the Consolidated Framework for Implementation Research (CFIR).⁴² RE-AIM is a multidimensional framework for evaluating the public health impact of efforts to translate research into practice.³⁹ The five dimensions of RE-AIM are reach of the intervention within the target population, effectiveness of the intervention, adoption by target staff members or settings, implementation consistency and quality, and maintenance of intervention delivery and effects.³⁸⁻⁴¹ CFIR is a pragmatic meta-theoretical framework that synthesizes constructs related to implementation of evidence-based interventions. The five overarching domains are intervention characteristics, outer setting, inner setting, characteristics of individuals, and process, and include a total of 37 constructs that can be used to understand what works, and why, in a certain setting.⁴² We collect quantitative and qualitative data on reach, effectiveness, adoption, implementation, and maintenance (RE-AIM) of the intervention. Quantitative data are collected as routine tracking as part of the implementation of both trials, with data on participation, intervention use, fidelity to the intervention, and changes over time (Table 2). Qualitative data are collected through short, semi-structured interviews (10-30 minutes) guided by the CFIR domains. The interviews are conducted in-person or by phone with patients (n=20) and family members (n=20) from Trial 2, and clinicians (n=50) from either Trial 1 or 2 after study involvement. All participants are selected using purposive sampling to ensure a diverse group based on level of participation, race, ethnicity, age, gender and, for clinicians, specialty, and year of training. A trained qualitative interviewer will interview participants using an interview guide, and interviews will be audio-recorded and transcribed.^{16,43-59.}

Table 1: Outcome measures and data collection

MAJOR OUTCOME MEASURES	CONCEPT	DATA COLLECTION: SOURCE & TIME
Aims 1 and 2 outcomes		
EHR documentation of goals-of-care discussion (Primary outcome for both Trials)	Goals-of-care discussion	EHR: 30 days post randomization
ICU use, ICU and hospital free days	Intensity of care	EHR: 30 days post randomization
7- and 30-day ICU and hospital readmissions	Intensity of care	EHR: 7 and 30 days following hospital discharge
Costs of care	Intensity of care/intervention costs	EHR: During hospital stay, 30 and 90 days post-randomization.
All-cause mortality at 90 days and 1 year	All-cause mortality	Washington State death certificates
Aim 2 outcomes (not used in Aim 1 since the Trial 1 is a pragmatic trial without contact with patients or family members)		
Patient/family-reported discussion of goals ^{9,25}	Goals-of-care discussion occurrence	Survey: 3-5 days & 4-6 weeks post-randomization

Quality of Communication (QOC) ^{24,26,28}	Quality of communication	Survey: 3-5 days post randomization
SUPPORT question ³¹	Goal-concordant care	Survey: 3-5 days & 4-6 weeks post-randomization
HADS – anxiety and depression ^{36,37}	Symptoms of anxiety & depression	Survey: 4-6 weeks post-randomization
EQ-5D-5L	Health-related QOL	Survey: 4-6 weeks post-randomization
Patient/family reported ED, hospitalization and outpatient utilization	Healthcare utilization	Survey: 4-6 weeks post-randomization
CollaboRATE ⁶⁰	Shared decision-making	Survey: 3-5 days post randomization

6) Analyses

We will follow the intention-to-treat principle for all analyses.

a) Primary Outcome (presence of goals of care discussion within 30 days after randomization)

The effect of intervention on the primary outcome will be quantified by the difference in proportions and evaluated with a linear regression model with robust standard errors. The predictor of interest is randomization arm (Clinician-facing Jumpstart or usual care for Trial 1; or Clinician-facing Jumpstart, Bi-directional Jumpstart, or usual care for Trial 2). The model will adjust for hospital site and ADRD status, since randomization is stratified on these factors. This model assumes the effect of intervention is the same for patients with and without ADRD. We will also include an interaction between randomization arm and ADRD, which allows the effect of intervention to vary by ADRD status and allows evaluation of the effect among those with and without ADRD. We will evaluate the timing of goals-of-care discussions with a Cox proportional hazards model.

b) Additional Outcomes

For the analysis of the other outcomes, we will use a strategy similar to that for the primary outcome. For continuous outcomes (e.g., ICU-free days, HADS score), the effect of intervention will be quantified by a difference in means. For survey outcomes which are collected at more than one time point after randomization, we will use a mixed model to account for the correlation between repeated measures. Our initial model will allow the average response to be different at each time point, but assume the intervention has the same effect at each time. We will also allow the effect of intervention to be different across time by including an interaction between time and intervention. The advantage of using the data at the multiple time points and a mixed model approach is that we can gain precision; it also allows for missing responses, assuming responses are missing at random. Missing data are more of an issue for the survey outcomes than the primary outcome; we will quantify the amount and type of missing data, evaluate associations of missingness with participant characteristics, and apply appropriate methods to account for missing data.⁶¹

c) Evaluate implementation and identify barriers and facilitators to future implementation.

We will perform thematic content analysis of transcribed interviews to explore feedback on the intervention, ways to improve intervention implementation, and aspects of care not adequately addressed by the intervention.⁶²⁻⁶⁴ Interview guides and analyses will be guided by the RE-AIM and CFIR frameworks as described above.³⁸⁻⁴² Qualitative data will be imported to analytic software (Dedoose), where investigators will perform the following analytic steps using an iterative approach to thematic analysis⁶⁵: 1) initially code

material, devising a coding framework and using that framework to reduce the text into smaller segments; 2) identify themes from the coded text; 3) construct thematic networks that include basic themes, organizing themes and global themes; 4) describe and summarize thematic networks; and 5) interpret patterns that have emerged in and across thematic networks.

d) Heterogeneity of treatment effects (text from grant)

We will examine specific a priori sub-groups for heterogeneity of treatment effects to see if the intervention has a differential impact on outcomes. We will examine primary diagnosis (including ADRD as noted in the Research Strategy, but also cancer, chronic pulmonary disease, and heart failure.) We will examine for HTE across the three hospitals. We will also explore the impact of patient and family member gender, age, and race/ethnicity on treatment effects. These analyses will use the same analytic approach as outlined above, with inclusion of an interaction between the treatment indicator and the variable of interest (patient age, for example), which is measured at enrollment (prior to randomization).

7) Sample size

a) Sample size considerations for the primary outcome

The focus for sample size considerations is the primary outcome: proportion of patients with documented goals-of-care discussions within 30 days after randomization.

Trial 1: With a total sample size of 2000 (1000 per group), two-sided significance level (α) of 0.05, and a variance estimate based on the proportion in the control group only, we have 80% power to detect a difference in proportions between those randomized to Clinician-facing Jumpstart and usual care of at least 0.06. We assumed a proportion in the control group of 0.54 based on preliminary data. If the total number of patients with ADRD in Trial 1 is 400 (200 per group), we would have 80% power with $\alpha=0.05$ to detect a difference in proportions of 0.14 among those with ADRD.

Trial 2: With a total sample size of 600 (200 per Clinician-facing Jumpstart, 200 per Bi-directional Jumpstart, and 200 per usual care), we have 80% power to detect a difference in proportions of 16% for each of the 3 pairwise comparisons assuming an overall $\alpha=0.05$ and a Bonferroni adjustment for the 3 comparisons ($\alpha=0.017$ for each comparison) and variance based on a proportion of 0.54.

b) Sample size for qualitative analyses

For Aim 3 qualitative analyses, it is important to achieve theoretical saturation (no new themes emerging).^{64,66} Based on our prior studies, we anticipate achieving saturation by 80 interviews for understanding patients/families and clinician perspectives.^{16,46,54-59} We will monitor for saturation and will recruit additional participants if needed.

8) Data management and quality control to achieve scientific rigor

This project requires the creation, maintenance, and analysis of a database that includes a variety of measures from multiple sources. This study, like all studies, depends on the quality of the data and therefore systematic data collection, quality control, and data-management procedures will be implemented: 1) protocols for data collection; 2) rigorous training, certification, and periodic re-training of study staff, with ongoing monitoring of adherence to protocols; 3) regular review of questionnaire response rates, respondent burden,⁶⁷ and missing items to identify and correct problems; 4) verification of all data through custom-designed data entry systems; and 5) weekly team meetings to provide feedback to study staff to ensure problems are resolved quickly. To

ensure reliability and validity of data, we will use our current methods for training and quality control.⁶⁸⁻⁷² Staff conducting EHR review will undergo the following training: instruction on the protocol, guided practice abstraction, and independent abstraction with reconciliation by a trainer.

9) Protocol modifications

1. Changes to inclusion/exclusion criteria for Trials 1 and 2 (except where noted)
 - a. Lowering the inclusion criteria age from ≥ 65 to ≥ 55 years
 - b. Removing “English speaking” as an inclusion criterion (Trial 1 only)
 - c. Adding hospital admission for a minimum of 12 hours as an inclusion criterion
 - d. Removing markers of frailty as an eligibility criterion
 - e. Adding pregnancy, suicide attempt and same-day discharge as exclusion criteria
 - f. Adding COVID-19 as a specific inclusion diagnosis (Trial 1 only)
2. Study design
 - a. For Trial 2, in addition to comparing the bi-directional (survey-based) Jumpstart Guide to the clinician-facing (EHR-based) Jumpstart guide, we will also include a third arm in which patients receive usual care.
 - b. We have increased the target sample size from $n=400$ to $n=600$ to accommodate the addition of a third “usual care” arm to the study.
 - c. We have modified the questionnaires that patients receive at baseline such that only patients in the bi-directional Jumpstart arm are presented with items that are used to create the bi-directional (survey-based) Jumpstart Guide. These items are an integral part of the bi-directional intervention and therefore not appropriate for the other arms to complete.
3. Procedures
 - a. Removing data collection for acute severity of illness (e.g., SOFA score) for Trial 2 and replacing with a NEWS score.
 - b. Revisions to instruments included in surveys for Trial 2
 - c. Increasing subject numbers for clinician interviews from 20 to 50 across both trials
 - d. Addition of demographic items (required by study sponsor, NIH) to the clinician interview
4. Materials
 - a. Updated instructional video for clinicians in Trial 1
 - b. Revision of the Jumpstart Guide into an HTML format as a delivery option. This version includes optional feedback buttons at the bottom (options: will definitely use; will use if time allows; maybe, will consider; not appropriate; will not see this patient; already done; opt out; other/free text)
 - c. Updated language and formatting for all versions of the Jumpstart Guide (patient, clinician EHR-based, and clinician survey-based) using a human-centered design approach.¹⁰

10) Potential limitations and alternative approaches

a) Including ADRD and other diseases in same study

Patients with ADRD receive different intensity of care at the end of life compared to other chronic diseases,^{73,74} and there may be differences in the effectiveness of the interventions. Our hypothesis is that these interventions will work for all diseases, but because of the unique issues of increasing ICU use among those with ADRD,^{73,74} we will target adequate sample size for patients with ADRD to be able to test this hypothesis for the primary outcome of each trial. We could have proposed separate trials for ADRD and other illnesses, but this would decrease the generalizability of the interventions.

b) Generalizability

This study occurs in a single healthcare system but includes three diverse hospitals thus enhancing generalizability.

c) Misclassification of goals-of-care discussions

Goals-of-care discussions may be misclassified for two reasons: 1) the sensitivity and specificity of the NLP/ML algorithm is not perfect; and 2) documentation of goals-of-care discussions in the EHR will never perfectly reflect actual discussions. This misclassification could affect outcome assessment and patient identification. For outcome assessment, we will assess the accuracy of the NLP/ML algorithm against manual EHR review in a randomly selected sample of patients to evaluate the extent of misclassification. For our final algorithm, we will use human abstractors to verify the first documentation of a goals-of-care discussion for each patient to maximize positive predictive value and specificity, as has been done by others.^{75,76} However, since our goal is to prompt and guide more discussions than would happen without the interventions, the limitations of the NLP/ML algorithm for patient identification do not invalidate the randomized trials. We could have included all hospitalized patients regardless of prior documentation, but we believe that untargeted prompts might limit the impact of the intervention. In addition, we will use the interviews in Aim 3 to understand clinicians' perspectives on the effect of misclassification.

d) Contamination

It is possible that this intervention might change behavior for clinicians caring for patients randomized to the comparator arms. Our prior studies suggest that most clinicians require a patient-specific prompt to have timely goals-of-care discussions, which may mitigate this concern.^{9,25} However, we will assess for an increase in goals-of-care discussions in the comparator groups over time, which might signify contamination or temporal trends, but could be used to assess the potential degree of contamination if present. This issue would bias the results toward the null hypothesis and only be a major issue for a negative study.

e) Scalability of surveys in Trial 2

Study staff will distribute surveys, which is challenging for implementation in clinical practice. Aim 3 will provide insights into how best to address scalability for implementation.

f) Objective assessments of the quality of goals of care discussions

Our NLP/ML approach identifies goals-of-care discussions without assessing their quality. Since our prior trials demonstrated increased patient assessed quality with the Jumpstart intervention, this is less of a concern.^{9,25} Future NLP/ML advances may permit quality assessments. Trial 2 assesses quality of communication from patient and family perspectives.

g) Costs assessments focus on UW Medicine

Cost assessments for Aim 1 are limited to costs available in the UW Medicine EHR, and we will not be able to assess costs from other healthcare systems after hospital discharge. Most of the benefits we anticipate for this intervention will occur during the hospitalization, although there may be ongoing reductions in costs after hospitalization related to changes in the goals of care as a result of the intervention. We will evaluate for such effects in Trial 2, and the limitation of not having access to these costs from outside UW Medicine in Trial 1 is diminished somewhat because this is a randomized trial.

11) Anticipated findings

These interventions use the EHR to identify patients who should have documentation of a goals-of-care discussion but do not, and then prompt and guide such discussions with either: a) a clinician-facing prompt and guide for clinicians only, along with information about prior advance care planning completed prior to the hospitalization; or b) a bi-directional, patient-specific intervention that provides patient-specific support to clinicians, patients and family members. We anticipate that both interventions will be effective compared to the usual care arm, and that this study will provide important options for healthcare systems. Economic analyses will allow us to evaluate the effect on costs of care, after factoring in the costs of implementing these interventions, to enhance dissemination. If either or both of these interventions are not effective, the results and the interviews in Aim 3 will provide important information to shape, direct and deliver future interventions.

References

1. Sudore RL, Lum HD, You JJ, et al. Defining Advance Care Planning for Adults: A Consensus Definition From a Multidisciplinary Delphi Panel. *J Pain Symptom Manage* 2017;53:821-32 e1.
2. Childers JW, Back AL, Tulskey JA, Arnold RM. REMAP: A Framework for Goals of Care Conversations. *J Oncol Pract* 2017;13:e844-e50.
3. Morrison RS, Meier DE, Arnold RM. What's Wrong With Advance Care Planning? *JAMA* 2021;326:1575-6.
4. Halpern SD. Toward Evidence-Based End-of-Life Care. *N Engl J Med* 2015;373:2001-3.
5. Halpern SD. Goal-Concordant Care - Searching for the Holy Grail. *N Engl J Med* 2019;381:1603-6.
6. Halpern SD, Loewenstein G, Volpp KG, et al. Default options in advance directives influence how patients set goals for end-of-life care. *Health Aff (Millwood)* 2013;32:408-17.
7. Mohan D, Sacks OA, O'Malley J, et al. A New Standard for Advance Care Planning (ACP) Conversations in the Hospital: Results from a Delphi Panel. *J Gen Intern Med* 2021;36:69-76.
8. Sudore RL, Heyland DK, Lum HD, et al. Outcomes That Define Successful Advance Care Planning: A Delphi Panel Consensus. *J Pain Symptom Manage* 2018;55:245-55 e8.
9. Curtis JR, Downey L, Back AL, et al. A patient and clinician communication-priming intervention increases patient-reported goals-of-care discussions between patients with serious illness and clinicians: a randomized trial. *JAMA Intern Med* 2018;178:930-40.
10. Abedini NC, Merel SE, Hicks KG, et al. Applying Human-Centered Design to Refinement of the Jumpstart Guide, a Clinician- and Patient-Facing Goals-of-Care Discussion Priming Tool. *J Pain Symptom Manage* 2021;62:1283-8.
11. National Quality Forum, Measure 1626: Patients Admitted to ICU who Have Care Preferences Documented within 48 hours (RAND Corporation). 2017. (Accessed January 2, 2018, at https://www.qualityforum.org/News_And_Resources/Endorsement_Summaries/Endorsement_Summaries.aspx.)
12. Back AL, Arnold RM, Baile WF, et al. Efficacy of communication skills training for giving bad news and discussing transitions to palliative care. *Arch Intern Med* 2007;167:453-60.
13. Back AL, Arnold RM, Tulskey JA, Baile WF, Fryer-Edwards KA. Teaching communication skills to medical oncology fellows. *J Clin Oncol* 2003;21:2433-6.
14. Curtis JR, Sathitranacheewin S, Starks H, et al. Using Electronic Health Records for Quality Measurement and Accountability in Care of the Seriously Ill: Opportunities and Challenges. *J Palliat Med* 2018;21:S52-S60.
15. Sudore RL, Schillinger D, Knight SJ, Fried TR. Uncertainty about advance care planning treatment preferences among diverse older adults. *J Health Commun* 2010;15 Suppl 2:159-71.

16. Curtis JR, Wenrich MD, Carline JD, Shannon SE, Ambrozy DM, Ramsey PG. Understanding physicians' skills at providing end-of-life care: Perspectives of patients, families, and health care workers. *J Gen Intern Med* 2001;16:41-9.
17. Steinhauser KE, Christakis NA, Clipp EC, McNeilly M, McIntyre LM, Tulsky JA. Factors considered important at the end of life by patients, family, physicians, and other care providers. *JAMA* 2000;284:2476-82.
18. Lee RY, Brumback LC, Lober WB, et al. Identifying Goals of Care Conversations in the Electronic Health Record Using Natural Language Processing and Machine Learning. *J Pain Symptom Manage* 2021;61:136-42 e2.
19. Curtis JR, Nielsen EL, Treece PD, et al. Effect of a quality-improvement intervention on end-of-life care in the intensive care unit: a randomized trial. *Am J Respir Crit Care Med* 2011;183:348-55.
20. Curtis JR, Treece PD, Nielsen EL, et al. Integrating palliative and critical care: evaluation of a quality-improvement intervention. *Am J Respir Crit Care Med* 2008;178:269-75.
21. Curtis JR, Treece PD, Nielsen EL, et al. Randomized Trial of Communication Facilitators to Reduce Family Distress and Intensity of End-of-Life Care. *Am J Respir Crit Care Med* 2016;193:154-62.
22. Khandelwal N, Brumback LC, Halpern SD, Coe NB, Brumback B, Curtis JR. Evaluating the Economic Impact of Palliative and End-of-Life Care Interventions on Intensive Care Unit Utilization and Costs from the Hospital and Healthcare System Perspective. *J Palliat Med* 2017;20:1314-20.
23. Auriemma CL, Taylor SP, Harhay MO, Courtright KR, Halpern SD. Hospital-Free Days: A Pragmatic and Patient-centered Outcome for Trials among Critically and Seriously Ill Patients. *Am J Respir Crit Care Med* 2021;204:902-9.
24. Engelberg R, Downey L, Curtis JR. Psychometric characteristics of a quality of communication questionnaire assessing communication about end-of-life care. *J Palliat Med* 2006;9:1086-98.
25. Au DH, Udris EM, Engelberg RA, et al. A randomized trial to improve communication about end-of-life care among patients with COPD. *Chest* 2012;141:726-35.
26. Curtis JR, Engelberg RA, Nielsen EL, Au DH, Patrick DL. Patient-physician communication about end-of-life care for patients with severe COPD. *Eur Respir J* 2004;24:200-5.
27. Curtis JR, Patrick DL, Caldwell E, Greenlee H, Collier AC. The quality of patient-clinician communication about end-of-life care: A study of patients with AIDS and their primary care clinicians. *AIDS* 1999;13:1123-31.
28. Janssen DJ, Curtis JR, Au DH, et al. Patient-clinician communication about end-of-life care for Dutch and US patients with COPD. *Eur Respir J* 2011;38:268-76.
29. Hanson LC, Zimmerman S, Song MK, et al. Effect of the Goals of Care Intervention for Advanced Dementia: A Randomized Clinical Trial. *JAMA Intern Med* 2017;177:24-31.
30. White DB, Angus DC, Shields AM, et al. A Randomized Trial of a Family-Support Intervention in Intensive Care Units. *N Engl J Med* 2018;378:2365-75.
31. Teno JM, Fisher ES, Hamel MB, Coppola K, Dawson NV. Medical care inconsistent with patients' treatment goals: association with 1-year Medicare resource use and survival. *J Am Geriatr Soc* 2002;50:496-500.
32. Coast J, Huynh E, Kinghorn P, Flynn T. Complex Valuation: Applying Ideas from the Complex Intervention Framework to Valuation of a New Measure for End-of-Life Care. *Pharmacoeconomics* 2016;34:499-508.
33. Finkelstein EA, Bilger M, Flynn TN, Malhotra C. Preferences for end-of-life care among community-dwelling older adults and patients with advanced cancer: A discrete choice experiment. *Health Policy* 2015;119:1482-9.
34. Flynn TN, Bilger M, Malhotra C, Finkelstein EA. Are Efficient Designs Used in Discrete Choice Experiments Too Difficult for Some Respondents? A Case Study Eliciting Preferences for End-of-Life Care. *Pharmacoeconomics* 2016;34:273-84.
35. Appelbaum PS. Clinical practice. Assessment of patients' competence to consent to treatment. *N Engl J Med* 2007;357:1834-40.
36. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. *Acta Psychiatr Scand* 1983;67:361-70.

37. Bjelland I, Dahl AA, Haug TT, Neckelmann D. The validity of the Hospital Anxiety and Depression Scale. An updated literature review. *J Psychosom Res* 2002;52:69-77.
38. Gaglio B, Shoup JA, Glasgow RE. The RE-AIM framework: a systematic review of use over time. *Am J Public Health* 2013;103:e38-46.
39. Glasgow RE, Vogt TM, Boles SM. Evaluating the public health impact of health promotion interventions: the RE-AIM framework. *Am J Public Health* 1999;89:1322-7.
40. Harden SM, Gaglio B, Shoup JA, et al. Fidelity to and comparative results across behavioral interventions evaluated through the RE-AIM framework: a systematic review. *Syst Rev* 2015;4:155.
41. Shoup JA, Gaglio B, Varda D, Glasgow RE. Network analysis of RE-AIM framework: chronology of the field and the connectivity of its contributors. *Transl Behav Med* 2015;5:216-32.
42. Damschroder LJ, Aron DC, Keith RE, Kirsh SR, Alexander JA, Lowery JC. Fostering implementation of health services research findings into practice: a consolidated framework for advancing implementation science. *Implement Sci* 2009;4:50.
43. Engelberg RA, Wenrich MD, Curtis JR. Responding to families' questions about the meaning of physical movements in critically ill patients. *J Crit Care* 2008;23:565-71.
44. Engelberg RA, Downey L, Wenrich MD, et al. Measuring the quality of end-of-life care. *J Pain Symptom Manage* 2010;39:951-71.
45. Howell AA, Nielsen EL, Turner AM, Curtis JR, Engelberg RA. Clinician perceptions of the role of an interprofessional communication facilitator to improve family outcomes in the ICU *Am J Crit Care* 2014;23:380-6.
46. Curtis JR, Engelberg R, Young JP, et al. An approach to understanding the interaction of hope and desire for explicit prognostic information among individuals with severe chronic obstructive pulmonary disease or advanced cancer. *J Palliat Med* 2008;11:610-20.
47. Curtis JR, Engelberg RA, Wenrich MD, Au DH. Communication about palliative care for patients with chronic obstructive pulmonary disease. *J Palliat Care* 2005;21:157-64.
48. Curtis JR, Engelberg RA, Wenrich MD, et al. Studying communication about end-of-life care during the ICU family conference: Development of a framework. *J Crit Care* 2002;17:147-60.
49. Curtis JR, Engelberg RA, Wenrich MD, Shannon SE, Treece PD, Rubenfeld GD. Missed opportunities during family conferences about end-of-life care in the intensive care unit. *Am J Respir Crit Care Med* 2005;171:844-9.
50. Reinke LF, Engelberg RA, Shannon SE, et al. Transitions regarding palliative and end-of-life care in severe chronic obstructive pulmonary disease or advanced cancer: themes identified by patients, families, and clinicians. *J Palliat Med* 2008;11:601-9.
51. Reinke LF, Shannon SE, Engelberg RA, Young JP, Curtis JR. Supporting hope and prognostic information: nurses' perspectives on their role when patients have life-limiting prognoses. *J Pain Symptom Manage* 2010;39:982-92.
52. West HF, Engelberg RA, Wenrich MD, Curtis JR. Expressions of nonabandonment during the intensive care unit family conference. *J Palliat Med* 2005;8:797-807.
53. White DB, Engelberg RA, Wenrich MD, Lo B, Curtis JR. Prognostication during physician-family discussions about limiting life support in intensive care units. *Crit Care Med* 2007;35:442-8.
54. Back AL, Young JP, McCown E, et al. Abandonment at the end of life from patient, caregiver, nurse, and physician perspectives: loss of continuity and lack of closure. *Arch Intern Med* 2009;169:474-9.
55. Carline JD, Curtis JR, Wenrich MD, Shannon SE, Ambrozy DM, Ramsey PG. Physicians' interactions with health care teams and systems in the care of dying patients: Perspectives of dying patients, family members, and health care providers. *J Pain Symptom Manage* 2003;25:19-28.
56. Curtis JR, Patrick DL, Caldwell E, Collier AC. Why don't patients with AIDS and their clinicians talk about end-of-life care? Barriers to communication for patients with AIDS and their primary care clinicians. *Arch Intern Med* 2000;160:1690-6.

57. Curtis JR, Wenrich MD, Carline JD, Shannon SE, Ambrozy DM, Ramsey PG. Patients' perspectives on physicians' skills at end-of-life care: Differences between patients with COPD, cancer, and AIDS. *Chest* 2002;122:356-62.
58. Wenrich MD, Curtis JR, Ambrozy DM, et al. Provision of emotional support and personalized care by physicians to patients nearing the end of life. *J Pain Symptom Manage* 2003;25:236-46.
59. Wenrich MD, Curtis JR, Shannon SE, Carline JD, Ambrozy DM, Ramsey PG. Communicating with dying patients within the spectrum of medical care from terminal diagnosis to death. *Arch Intern Med* 2001;161:868-74.
60. Elwyn G, Barr PJ, Grande SW, Thompson R, Walsh T, Ozanne EM. Developing CollaboRATE: a fast and frugal patient-reported measure of shared decision making in clinical encounters. *Patient Educ Couns* 2013;93:102-7.
61. Little R, Rubin D. *Statistical analysis with missing data*. Third ed. New York: Wiley; 2019.
62. Hsieh HF, Shannon SE. Three approaches to qualitative content analysis. *Qual Health Res* 2005;15:1277-88.
63. Corbin J, Strauss A. *Methods of qualitative research*. Thousand Oaks, CA: Sage Publications; 1993.
64. Strauss AL, Corbin J. *Basics of Qualitative Research: Techniques and Procedures for Developing Grounded Theory*. Thousand Oaks: Sage Publications; 1998.
65. Attride-Stirling J. Thematic networks: An analytic tool for qualitative research. *Qualitative Research* 2001;1:385-405.
66. Giacomini M, Cook DJ, for the Evidence-Based Medicine Working Group. Qualitative research in health care: What are the results and how do they help me care for my patients? *JAMA* 2000;284:478-82.
67. Kross EK, Nielsen EL, Curtis JR, Engelberg RA. Survey burden for family members surveyed about end-of-life care in the intensive care unit. *J Pain Symptom Manage* 2012;44:671-80.
68. Glavan BJ, Engelberg RA, Downey L, Curtis JR. Using the medical record to evaluate the quality of end-of-life care in the intensive care unit. *Crit Care Med* 2008;36:1138-46.
69. Gries CJ, Engelberg RA, Kross EK, et al. Predictors of symptoms of posttraumatic stress and depression in family members after patient death in the ICU. *Chest* 2010;137:280-7.
70. Gries CJ, Curtis JR, Wall RJ, Engelberg RA. Family member satisfaction with end-of-life decision making in the ICU. *Chest* 2008;133:704-12.
71. Gerstel E, Engelberg RA, Koepsell T, Curtis JR. Duration of withdrawal of life support in the intensive care unit and association with family satisfaction. *Am J Respir Crit Care Med* 2008;178:798-804.
72. Kross EK, Engelberg RA, Gries CJ, Nielsen EL, Zatzick D, Curtis JR. ICU care associated with symptoms of depression and posttraumatic stress disorder among family members of patients who die in the ICU. *Chest* 2011;139:795-801.
73. Curtis JR, Engelberg RA, Teno JM. Understanding variability in end-of-life care in the ICU for the elderly. *Intensive Care Medicine* 2017;43:94-6.
74. Teno JM, Gozalo P, Khandelwal N, et al. Association of Increasing Use of Mechanical Ventilation Among Nursing Home Residents With Advanced Dementia and Intensive Care Unit Beds. *JAMA Intern Med* 2016;176:1809-16.
75. Udelsman B, Chien I, Ouchi K, Brizzi K, Tulskey JA, Lindvall C. Needle in a Haystack: Natural Language Processing to Identify Serious Illness. *J Palliat Med* 2019;22:179-82.
76. Lindvall C, Deng CY, Moseley E, et al. Natural Language Processing to Identify Advance Care Planning Documentation in a Multisite Pragmatic Clinical Trial. *J Pain Symptom Manage* 2022;63:e29-e36.